A Prospective, Single-arm, Multicenter Exploratory Clinical Study of Anlotinib Combined With Bempegaldesleukin and Conventional Chemoradiotherapy for the Treatment of Unresectable Locally Advanced or Metastatic Soft Tissue Sarcoma.
Clinical trial NCT07156643 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07156643
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-10-01
- Primary completion
- 2030-10-01
- Enrollment
- 46
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.